ZA200804006B - EGFR dependant modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effets thereof - Google Patents

EGFR dependant modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effets thereof

Info

Publication number
ZA200804006B
ZA200804006B ZA200804006A ZA200804006A ZA200804006B ZA 200804006 B ZA200804006 B ZA 200804006B ZA 200804006 A ZA200804006 A ZA 200804006A ZA 200804006 A ZA200804006 A ZA 200804006A ZA 200804006 B ZA200804006 B ZA 200804006B
Authority
ZA
South Africa
Prior art keywords
egfr
tumors
diagnosis
therapy
influence
Prior art date
Application number
ZA200804006A
Other languages
English (en)
Inventor
Sutter Arne
Behrens Joyce
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ZA200804006B publication Critical patent/ZA200804006B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200804006A 2005-10-11 2008-05-09 EGFR dependant modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effets thereof ZA200804006B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05022127 2005-10-11

Publications (1)

Publication Number Publication Date
ZA200804006B true ZA200804006B (en) 2009-03-25

Family

ID=37460022

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200804006A ZA200804006B (en) 2005-10-11 2008-05-09 EGFR dependant modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effets thereof

Country Status (12)

Country Link
US (2) US20080199850A1 (fr)
EP (2) EP2251688A1 (fr)
JP (1) JP2009511524A (fr)
KR (1) KR20080068848A (fr)
CN (1) CN101283275A (fr)
AU (1) AU2006301518B2 (fr)
BR (1) BRPI0617236A2 (fr)
CA (1) CA2625291A1 (fr)
EA (1) EA014433B1 (fr)
IL (1) IL190537A (fr)
WO (1) WO2007042286A1 (fr)
ZA (1) ZA200804006B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8668926B1 (en) 2003-09-15 2014-03-11 Shaker A. Mousa Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
WO2005027895A2 (fr) 2003-09-15 2005-03-31 Ordway Research Institute Analogues d'hormone thyroidienne et methodes d'utilisation associees
US9498536B2 (en) * 2005-09-15 2016-11-22 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders
US10130686B2 (en) * 2005-09-15 2018-11-20 Nanopharmaceuticals Llc Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders
EP2390366A1 (fr) * 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Procédé d'identification si un patient est réactif ou non à l'immunothérapie basé sur l'expression différentielle du gène TRAT1
US8498695B2 (en) 2006-12-22 2013-07-30 Novadaq Technologies Inc. Imaging system with a single color image sensor for simultaneous fluorescence and color video endoscopy
US20080269339A1 (en) * 2007-04-26 2008-10-30 Thomas Robert Sutter Combined use of egf pathway inhibitors and differentiation promoting compounds
BRPI0906187A2 (pt) 2008-03-18 2020-07-14 Novadaq Technologies Inc. método e sistema de representação de imagens para aquisição de imagens nir e imagens em cor total
WO2010148007A2 (fr) 2009-06-17 2010-12-23 Ordway Research Institute, Inc. Formulations nanoparticulaires et polymères pour hormone thyroïdienne, analogues, antagonistes et formulations et utilisations de celles-ci
WO2015074050A1 (fr) 2013-11-18 2015-05-21 Nanopharmaceuticals Llc Procédés de dépistage de patients ayant une résistance à l'angio-inhibition, traitement et prophylaxie pour ceux-ci
WO2017049237A1 (fr) * 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Approche personnalisée de dosage d'un agent antichimiorépulsion pour le traitement du cancer
WO2017127929A1 (fr) 2016-01-26 2017-08-03 Novadaq Technologies Inc. Plateforme configurable
USD916294S1 (en) 2016-04-28 2021-04-13 Stryker European Operations Limited Illumination and imaging device
CN109715551A (zh) 2016-06-07 2019-05-03 纳米药业有限责任公司 与αvβ3整联蛋白甲状腺拮抗剂缀合的不可裂解聚合物
WO2017214730A1 (fr) 2016-06-14 2017-12-21 Novadaq Technologies Inc. Procédés et systèmes d'imagerie adaptative pour l'amélioration des signaux en faible lumière dans la visualisation médicale
CA3049922A1 (fr) 2017-02-10 2018-08-16 Novadaq Technologies ULC Systemes et procedes d'imagerie a fluorescence portative a champ ouvert
CN111601617A (zh) 2017-12-13 2020-08-28 上海岸阔医药科技有限公司 一种用于预防或治疗与egfr 被抑制相关疾病的方法
US11351137B2 (en) 2018-04-11 2022-06-07 Nanopharmaceuticals Llc Composition and method for dual targeting in treatment of neuroendocrine tumors
US10328043B1 (en) 2018-04-11 2019-06-25 Nanopharmaceuticals, Llc. Composition and method for dual targeting in treatment of neuroendocrine tumors
WO2019201195A1 (fr) 2018-04-16 2019-10-24 上海岸阔医药科技有限公司 Méthode pour prévenir ou traiter les effets secondaires d'une cancérothérapie
US10961204B1 (en) 2020-04-29 2021-03-30 Nanopharmaceuticals Llc Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors
US11723888B2 (en) 2021-12-09 2023-08-15 Nanopharmaceuticals Llc Polymer conjugated thyrointegrin antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
EP1362868A3 (fr) 1991-03-06 2004-02-11 MERCK PATENT GmbH Anticorps monoclonaux humanisés et chimériques se liant au récepteur du facteur de croissance épidermique (EGF-R)
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
ATE165097T1 (de) 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5650407A (en) 1995-04-05 1997-07-22 Cephalon, Inc. Selected soluble esters of hydroxyl-containing indolocarbazoles

Also Published As

Publication number Publication date
EA200800963A1 (ru) 2008-10-30
KR20080068848A (ko) 2008-07-24
JP2009511524A (ja) 2009-03-19
CN101283275A (zh) 2008-10-08
US20080199850A1 (en) 2008-08-21
IL190537A0 (en) 2008-11-03
EA014433B1 (ru) 2010-12-30
IL190537A (en) 2011-04-28
AU2006301518A1 (en) 2007-04-19
CA2625291A1 (fr) 2007-04-19
US20110244506A1 (en) 2011-10-06
BRPI0617236A2 (pt) 2011-07-19
EP2251688A1 (fr) 2010-11-17
WO2007042286A1 (fr) 2007-04-19
EP1934599A1 (fr) 2008-06-25
AU2006301518B2 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
ZA200804006B (en) EGFR dependant modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effets thereof
EP1814909A4 (fr) Utilisation de aimp2dx2 pour diagnostiquer et traiter un cancer
HUS1700015I1 (hu) PDGFR-alfa elleni antitest és alkalmazása tumorok kezelésénél
EP2046973A4 (fr) Procédés d'identification, d'évaluation, et de traitement de patients soumis à une thérapie anticancéreuse
EP1804917A4 (fr) Systeme de traitement de tumeur dynamique
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
EP1811844A4 (fr) Méthodes de diagnostic et de traitement du cancer
EP1816953A4 (fr) Instrument de detection et de traitement du cancer
WO2006015263A3 (fr) Analogues de lonidamine
EP1720575A4 (fr) Conjugues therapeutiques et diagnostiques utilisables avec des anticorps multispecifiques
EP1718602A4 (fr) Molecules porteuses et therapeutiques
IL186447A0 (en) Methods for the treatment of substance abuse and dependence
EP1940456A4 (fr) Gene wwox, vecteurs renfermant celui-ci et utilisations de ceux-ci dans le traitement de cancer
IL187898A0 (en) Parp modulators and treatment of cancer
WO2008073899A3 (fr) Compositions associées à prrg4 et procédés d'utilisation de celles-ci dans des procédés de diagnostic de tumeur
HK1157361A1 (en) Diagnosis and treatment of cancer using anti-gpr49 antibody gpr49
PL2450041T3 (pl) Ulepszony żel zawierający testosteron do zastosowania do leczenia hipogonadyzmu
EP1587837A3 (fr) Diagnostic et traitement du cancer de la prostate
WO2009009587A3 (fr) Thérapie à base de protéines modulant l'apoptose pour traiter les troubles prolifératifs et nanoparticules les contenant
HK1164767A1 (en) Compounds and methods for the treatment of cancer
WO2010054377A3 (fr) Anticorps entièrement humains dirigés contre la n-cadhérine
HK1150401A1 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
ZA200510282B (en) Compositions and methods for the diagnosis and treatment of tumor
EP1934331A4 (fr) Ciblage de pax2 en vue d'induire le traitement du cancer et l'immunite tumorale induite par defb1
EP1781826A4 (fr) Compositions et techniques de diagnostic et de traitement d'orthopoxvirus